CIK 0001720580
- Non-accelerated filer
- Smaller reporting company
Adicet Bio, Inc.
Sign in to watch- Ticker
- ACET
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 26
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813305277
- Phone
- +1 617-482-2333
- Business address
- 131 DARTMOUTH STREET, 3RD FLOOR, BOSTON, MA, 02116
- Former names
- resTORbio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 50 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-10 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion | +6,036 | $13.27 | $80K | 65,953 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Sale | −6,036 | $21.00 | $127K | 59,917 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion | +168 | $5.97 | $1K | 60,085 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Sale | −168 | $21.00 | $4K | 59,917 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion | +1,775 | $16.82 | $30K | 61,692 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Sale | −1,775 | $21.00 | $37K | 59,917 |
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −6,036 | 73,964 | ||
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −168 | 113,652 | ||
| 2022-04-04 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −1,775 | 26,625 | ||
| 2022-04-01 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion | +7,621 | $5.97 | $45K | 67,538 |
| 2022-04-01 | Galimi Francesco SVP & Chief Medical Officer | Sale | −7,621 | $21.00 | $160K | 59,917 |
| 2022-04-01 | Galimi Francesco SVP & Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −7,621 | 113,820 | ||
| 2022-03-09 | Jakobovits Aya Director | Sale | −2,000 | $14.00 | $28K | 356,343 |
| 2022-03-09 | Jakobovits Aya Director | Sale | −2,000 | $14.00 | $28K | 356,345 |
| 2022-02-16 | Jakobovits Aya Director | Sale | −2,000 | $14.83 | $30K | 358,343 |
| 2022-02-16 | Jakobovits Aya Director | Sale | −2,000 | $14.83 | $30K | 358,345 |
| 2022-02-14 | Healey Don Chief Technology Officer | Grant or award | +16,000 | 58,467 | ||
| 2022-02-14 | Healey Don Chief Technology Officer | Shares withheld for taxes | −5,533 | $14.27 | $79K | 52,934 |
| 2022-02-14 | Aftab Blake Chief Scientific Officer | Grant or award | +16,000 | 58,436 |
Page 18 of 24 · 478 trades